Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   

What is dementia?

quality sleep1 - alzheimer's causes1 - arnold pick1 - blood test1 - mild tremor1 - cognitive functions1 - alcohol consumption1 - alzheimer's and parkinson's diseases1 - neel nabar1 - carus1 - simplicity1 - emotional distress1 - long-term memory1 - slowed movement1 - insomnia2 - idiocy1 - delusional misidentification1 - short-term memory problems1 - grandiosity1 - quetiapine1 - α-synuclein2 - cognition2 - references1 - behavioural syndrome1 - historical hypotheses1 - pre-dementia stage1 - behaviours redolent1 - brain structure1 - early alzheimer's3 - greek paranoia1 -